|
1.
|
M MasaroneM PersicoAntiviral therapy: why
does it fail in HCV-related chronic hepatitis?Expert Rev Anti
Infect Ther9535543201110.1586/eri.11.1021609265
|
|
2.
|
M RipoliV PazienzaImpact of HCV genetic
differences on pathobiology of diseaseExpert Rev Anti Infect
Ther9747759201110.1586/eri.11.9421905784
|
|
3.
|
GG XuSM WuXQ ZhouClinical characteristics
of 638 patients infected with hepatitis C virus by post blood
transfusion, in ShanghaiZhonghua Liu Xing Bing Xue Za
Zhi323883912011(In Chinese)
|
|
4.
|
DA SteinhauerE DomingoJJ HollandLack of
evidence for proofreading mechanisms associated with an RNA virus
polymeraseGene122281288199210.1016/0378-1119(92)90216-C1336756
|
|
5.
|
A NeumannN LamH DahariHepatitis C viral
dynamics in vivo and the antiviral efficacy of interferon-alpha
therapyScience282103107199810.1126/science.282.5386.103
|
|
6.
|
M MartellJI EstebanJ QuerHepatitis C virus
(HCV) circulates as a population of different but closely related
genomes: quasispecies nature of HCV genome distributionJ
Virol663225322919921313927
|
|
7.
|
JM PawlotskyHepatitis C virus population
dynamics during infectionCurr Top Microbiol
Immunol299261284200616568902
|
|
8.
|
C ArgentiniD GenoveseS DettoriM
RapicettaHCV genetic variability: from quasispecies evolution to
genotype classificationFuture
Microbiol4359373200910.2217/fmb.09.819327119
|
|
9.
|
MM ElHefnawiS ZadaIA El-AzabPrediction of
prognostic biomarkers for interferon-based therapy to hepatitis C
virus patients: a meta-analysis of the NS5A protein in subtypes 1a,
1b, and 3aVirol J15130201010.1186/1743-422X-7-13020550652
|
|
10.
|
BI YehKH HanHW LeeFactors predictive of
response to interferon-alpha therapy in hepatitis C virus type 1b
infectionJ Med Virol66481487200210.1002/jmv.216911857525
|
|
11.
|
I AbbateO Lo IaconoR Di StefanoHVR-1
quasispecies modifications occur early and are correlated to
initial but not sustained response in HCV-infected patients treated
with pegylated-or standard-interferon and ribavirinJ
Hepatol40831836200410.1016/j.jhep.2004.01.019
|
|
12.
|
G SquadritoG RaffaT RestucciaIs
investigation of hepatitis C virus NS5A gene heterogeneity a tool
for predicting long-lasting response to interferon therapy in
patients with HCV-1b chronic hepatitis?J Viral
Hepat9360369200210.1046/j.1365-2893.2002.00379.x12225331
|
|
13.
|
L ZhangGZ ZhaoY LiDynamic changes of HVR1
quasispecies in chronic hepatitis C after IFN therapyWorld Chin J
Digestol111821842003(In Chinese)
|
|
14.
|
P FaciA ShimodaD WongPrevention of
hepatitis C virus infection in chimpanzees by hyperimmune serum
against the hypervariable region 1 of the envelope 2 proteinProc
Natl Acad Sci
USA931539415399199610.1073/pnas.93.26.153948986822
|
|
15.
|
YK ShimizuH IgarashiT KiyoharaA
hyperimmune serum against a synthetic peptide corresponding to the
hyper-variable region 1 of hepatitis C virus can prevent viral
infection in cell
culturesVirology223409412199610.1006/viro.1996.0497
|
|
16.
|
N EnomotoI SakumaY AsahinaMutations in the
nonstructural protein 5A gene and response to interferon in
patients with chronic hepatitis C 1b infectionN Engl J
Med3347781199610.1056/NEJM1996011133402038531962
|
|
17.
|
M GerottoF Dal PeroP PontissoTwo PKR
inhibitor HCV proteins correlate with early but not sustained
response to
interferonGastroenterology11916491655200010.1053/gast.2000.2023011113086
|
|
18.
|
H KhorsiS CsatelainA WyseurMutations of
hepatitis C virus 1b NS5A 2209–2248 amino acid sequence
do not predict the response to recombinant interferon-alfa therapy
in French patientsJ Hepatol27727719979252076
|
|
19.
|
S ZeuzemJH LeeWK RothMutations in the
nonstructural protein 5A gene of European hepatitis C virus
isolates and response to interferon
alphaHepatology25740744199710.1002/hep.5102503419049228
|
|
20.
|
K ChayamaF SuzukiA TsubotaAssociation of
amino acid sequence in the PKR-eIF2 phosphorylation homology domain
and response to interferon
therapyHepatology3211381144200010.1053/jhep.2000.1936411050067
|
